H. Ollikainen et al., P53 GENE-MUTATIONS ARE RARE IN PATIENTS BUT COMMON IN PATIENT-ORIGINATING CELL-LINES IN MULTIPLE-MYELOMA, Scandinavian journal of clinical & laboratory investigation, 57(4), 1997, pp. 281-289
We have shown previously that detectable serum concentration of p53 pr
otein is associated with poor prognosis in multiple myeloma (MM). In t
his study, we studied p53 gene mutations in 29 bone marrow samples of
MM patients using polymerase chain reaction-single-strand conformation
polymorphism (PCR-SSCP) and direct sequencing. No p53 mutations were
found in these patients although 41% of the patients had an elevated s
erum p53 protein concentration. This result indicates that the detecta
ble serum level of p53 protein is not associated with p53 mutations. I
n addition, we have also analysed three MM cell Lines established from
bone marrow samples. All the cell lines contained p53 mutations in ex
on 5. However, bone marrow samples of the patients associated with the
cell lines did not have these mutations at the time of diagnosis, nor
did the original samples which were used to establish the cell lines.
This indicates that p53 mutations can arise during the cell passages.